A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naïve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results.
2019
561Background:
Pazopanibas single agent and
bevacizumabplus interferon were approved for use in metastatic RCC (MRCC) based on their ability to modulate the vasculature and prolong progression fr...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI